Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Anastrozole
Drug ID BADD_D00142
Description Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne.[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]
Indications and Usage Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women.[L8863] It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with [tamoxifen].[L8866,L8863]
Marketing Status approved; investigational
ATC Code L02BG03
DrugBank ID DB01217
KEGG ID D00960
MeSH ID D000077384
PubChem ID 2187
TTD Drug ID D0W0BF
NDC Product Code 38779-2555; 58623-0041; 73377-120; 65841-743; 70518-2420; 0310-0201; 51927-4435; 68071-1543; 68071-2791; 46014-1009; 69988-0013; 71052-248; 63187-080; 63629-5269; 70518-2484; 59651-236; 63850-0010; 71335-1879; 0904-6195; 46014-1160; 61200-104; 68554-0026; 16571-421; 0093-7536; 51991-620; 68382-209; 63850-6527; 50090-2453; 50090-5812; 68001-155; 65072-0702; 65129-1119; 16729-035; 42291-016; 50268-075; 60687-112; 68071-5203; 62991-3176; 43063-383; 62559-670; 72789-008; 55111-814; 62135-490; 72189-415; 53104-7627; 65096-0117; 42291-085; 76420-004; 51552-1568; 60440-2921; 62157-077; 62756-428; 82393-201
UNII 2Z07MYW1AZ
Synonyms Anastrozole | 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) | Anastrazole | Arimidex | ICI D1033 | ZD-1033 | ZD 1033 | Zeneca ZD 1033 | ZD1033
Chemical Information
Molecular Formula C17H19N5
CAS Registry Number 120511-73-1
SMILES CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute kidney injury20.01.03.0160.001509%
Posterior reversible encephalopathy syndrome17.13.02.0070.000238%
Functional gastrointestinal disorder07.11.01.016--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.001271%Not Available
Intraductal proliferative breast lesion21.05.01.014; 16.10.01.0060.000318%Not Available
Reversible cerebral vasoconstriction syndrome24.04.06.026; 17.08.02.014; 18.06.01.0040.000318%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.000397%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000477%
Liver function test increased13.03.04.031--Not Available
Antiphospholipid syndrome24.01.01.029; 18.02.04.002; 10.04.01.009; 01.01.02.0160.000556%Not Available
Bone cancer16.29.02.002; 15.09.03.0120.000159%Not Available
Breast cancer recurrent21.05.01.017; 16.10.01.0090.001748%Not Available
Breast cancer stage I21.05.01.018; 16.10.01.010--Not Available
Endometrial cancer metastatic21.07.02.012; 16.12.02.0040.000159%Not Available
Malignant pleural effusion22.05.04.001; 16.32.03.0140.000238%Not Available
Mesenteric vein thrombosis24.01.08.004; 07.15.02.0130.000238%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.003416%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000953%Not Available
Metastases to pleura22.05.04.002; 16.22.02.0220.000238%Not Available
Recurrent cancer16.16.01.0150.000159%Not Available
Pancreatic mass07.18.02.0070.000159%Not Available
Metastases to heart16.22.02.016; 02.10.01.0020.000159%Not Available
Tongue haemorrhage24.07.02.058; 07.14.01.015--Not Available
Anti-neutrophil cytoplasmic antibody positive vasculitis10.02.02.023; 24.12.04.0020.000159%Not Available
Metastases to bone marrow16.22.02.013; 01.05.01.0220.000159%Not Available
Non-alcoholic steatohepatitis09.01.07.035; 14.08.04.0240.000318%Not Available
Breast cancer metastatic21.05.01.016; 16.10.01.0080.001827%Not Available
Tenosynovitis stenosans15.07.01.0130.000159%Not Available
Hepatic mass09.01.08.0150.000159%Not Available
Vitreous adhesions06.09.01.0110.000238%Not Available
The 15th Page    First    Pre   15 16    Next   Last    Total 16 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene